================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------
FORM 8-K
----------
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
September 23, 2004
------------------------------------------------
Date of report (date of earliest event reported)
EMISPHERE TECHNOLOGIES, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware
----------------------------------------------
(State or other jurisdiction of incorporation)
1-10615
------------------------
(Commission File Number)
13-3306985
---------------------------------------
(I.R.S. Employer Identification Number)
765 Old Saw Mill River Road, Tarrytown, New York 10591
------------------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
914-347-2220
----------------------------------------------------
(Registrant's telephone number, including area code)
N/A
-------------------------------------------------------------
(Former name or former address, if changed since last report)
================================================================================
ITEM 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.
On September 23, 2004, Emisphere Technologies, Inc. announced that it has
entered into a licensing agreement with Novartis Pharma AG to develop an oral
formulation of recombinant human growth hormone (rhGH), following successful
completion of pre-clinical feasibility studies for rhGH with Emisphere's
eligen(R) technology.
Under the terms of the new agreement, Novartis will pay Emisphere up to $34
million during the course of product development, and a royalty increasing to
double-digit rates based upon sales. Including the initial payment, Emisphere
could receive up to $6 million over the course of the next year. Emisphere will
work with Novartis to initiate clinical trials of a convenient, oral human
growth hormone product using its eligen(R) technology. Novartis will fully fund
the program including all clinical studies.
Attached hereto and incorporated by reference herein as Exhibit 99.1 is a copy
of such press release.
Exhibit Number Description
-------------- -----------
Exhibit 99.1 Press Release of Emisphere Technologies, Inc.
dated September 23, 2004.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
EMISPHERE TECHNOLOGIES, INC.
Date: September 23, 2004 By:
---------------------------------
Name: Michael Goldberg
Title: Chief Executive Officer
3
EXHIBIT INDEX
Exhibit
Number Description
------- -----------
99.1 Press Release, issued September 23, 2004.
4